Kiora Pharmaceuticals Analyst Ratings
Kiora Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 483.33% | HC Wainwright & Co. | → $3.5 | Reiterates | Buy → Buy |
| 11/06/2023 | 483.33% | HC Wainwright & Co. | $2 → $3.5 | Maintains | Buy |
| 08/24/2023 | 233.33% | HC Wainwright & Co. | → $2 | Reiterates | Buy → Buy |
| 08/14/2023 | 233.33% | HC Wainwright & Co. | $7 → $2 | Maintains | Buy |
| 08/09/2023 | 233.33% | Maxim Group | $12 → $2 | Maintains | Buy |
| 05/12/2023 | 1066.67% | HC Wainwright & Co. | $6 → $7 | Maintains | Buy |
| 03/24/2023 | 900% | HC Wainwright & Co. | $10 → $6 | Reiterates | → Buy |
| 02/09/2023 | 1900% | Maxim Group | → $12 | Upgrades | Hold → Buy |
| 02/08/2023 | 1566.67% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 02/08/2023 | 19733.33% | Ladenburg Thalmann | → $119 | Reiterates | → Buy |
| 08/25/2022 | 983.33% | Ladenburg Thalmann | → $6.5 | Initiates Coverage On | → Buy |
| 08/15/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 07/11/2022 | 316.67% | HC Wainwright & Co. | $3 → $2.5 | Maintains | Buy |
| 04/19/2022 | 400% | HC Wainwright & Co. | $5 → $3 | Maintains | Buy |
| 01/19/2022 | 316.67% | Maxim Group | → $2.5 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析师事务所 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/13/2023 | 483.33% | HC Wainwright & Co. | → 3.5 美元 | 重申 | 购买 → 购买 |
| 11/06/2023 | 483.33% | HC Wainwright & Co. | $2 → 3.5 美元 | 维护 | 购买 |
| 08/24/2023 | 233.33% | HC Wainwright & Co. | → 2 美元 | 重申 | 购买 → 购买 |
| 08/14/2023 | 233.33% | HC Wainwright & Co. | 7 美元 → 2 美元 | 维护 | 购买 |
| 08/09/2023 | 233.33% | Maxim 集团 | 12 美元 → 2 美元 | 维护 | 购买 |
| 05/12/2023 | 1066.67% | HC Wainwright & Co. | 6 美元 → 7 美元 | 维护 | 购买 |
| 2023 年 3 月 24 日 | 900% | HC Wainwright & Co. | 10 美元 → 6 美元 | 重申 | → 购买 |
| 02/09/2023 | 1900% | Maxim 集团 | → 12 美元 | 升级 | 持有 → 买入 |
| 02/08/2023 | 1566.67% | HC Wainwright & Co. | → 10 美元 | 重申 | → 购买 |
| 02/08/2023 | 19733.33% | 拉登堡塔尔曼 | → 119 美元 | 重申 | → 购买 |
| 08/25/2022 | 983.33% | 拉登堡塔尔曼 | → 6.5 美元 | 启动覆盖范围开启 | → 购买 |
| 08/15/2022 | — | Maxim 集团 | 降级 | 买入 → 持有 | |
| 2022 年 11 月 7 日 | 316.67% | HC Wainwright & Co. | $3 → 2.5 美元 | 维护 | 购买 |
| 04/19/2022 | 400% | HC Wainwright & Co. | 5 美元 → 3 美元 | 维护 | 购买 |
| 2022 年 1 月 19 日 | 316.67% | Maxim 集团 | → 2.5 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Kiora Pharmaceuticals (KPRX)?
Kiora Pharmicals（KPRX）的目标价格是多少？
The latest price target for Kiora Pharmaceuticals (NASDAQ: KPRX) was reported by HC Wainwright & Co. on November 13, 2023. The analyst firm set a price target for $3.50 expecting KPRX to rise to within 12 months (a possible 483.33% upside). 10 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月13日公布了Kiora Pharmicals（纳斯达克股票代码：KPRX）的最新目标股价。该分析公司将目标股价定为3.50美元，预计KPRX将在12个月内上涨至3.50美元（可能上涨483.33％）。去年有10家分析公司公布了评级。
What is the most recent analyst rating for Kiora Pharmaceuticals (KPRX)?
Kiora Pharmicals（KPRX）的最新分析师评级是多少？
The latest analyst rating for Kiora Pharmaceuticals (NASDAQ: KPRX) was provided by HC Wainwright & Co., and Kiora Pharmaceuticals reiterated their buy rating.
Kiora Pharmicals（纳斯达克股票代码：KPRX）的最新分析师评级由HC Wainwright & Co. 提供，基奥拉制药重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Kiora Pharmaceuticals (KPRX)?
Kiora Pharmicals（KPRX）的下一个分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiora Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiora Pharmaceuticals was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Kiora Pharmicals的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。Kiora Pharmicals的最新评级是在2023年11月13日提交的，因此您应该预计下一个评级将在2024年11月13日左右公布。
Is the Analyst Rating Kiora Pharmaceuticals (KPRX) correct?
分析师评级Kiora Pharmicals（KPRX）是否正确？
While ratings are subjective and will change, the latest Kiora Pharmaceuticals (KPRX) rating was a reiterated with a price target of $0.00 to $3.50. The current price Kiora Pharmaceuticals (KPRX) is trading at is $0.60, which is within the analyst's predicted range.
尽管评级是主观的，并将发生变化，但Kiora Pharmicals（KPRX）的最新评级得到了重申，目标股价为0.00美元至3.50美元。Kiora Pharmicals（KPRX）目前的交易价格为0.60美元，在分析师的预测区间内。